gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Opioid growth factor receptor

OGFr, opioid growth factor receptor
The protein encoded by this gene is a receptor for opioid growth factor (OGF), also known as [Met(5)]-enkephalin. OGF is a negative regulator of cell proliferation and tissue organization in a variety of processes. The encoded unbound receptor for OGF has been localized to the outer nuclear envelope, where it binds OGF and is translocated into the nucleus. The coding sequence of this gene contains a polymorphic region of 60 nt tandem imperfect repeat units. Several transcripts containing between zero and eight repeat units have been reported. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Enkephalin, HAD, PCNA, CAN, p21
Papers on OGFr
Antagonism of the met5-enkephalin-opioid growth factor receptor-signaling axis promotes MSC to differentiate into osteoblasts.
New
Margulies et al., In J Orthop Res, Jan 2016
The opioid growth factor receptor (OGFR) is a non-canonical opioid receptor that binds naloxone with high affinity while the native opioid growth factor, met5-enkephalin (met5), binds both the OGFR and the canonical delta opioid receptor (OPRD).
Duration of opioid receptor blockade determines biotherapeutic response.
Review
New
Zagon et al., United States. In Biochem Pharmacol, Nov 2015
With the discovery of the opioid growth factor (OGF)-OGF receptor (OGFr) axis as a novel biological pathway involved in homeostasis of replicating cells and tissues, the role of opioid receptor antagonists was expanded.
Nuclear export of opioid growth factor receptor is CRM1 dependent.
New
McLaughlin et al., United States. In Exp Biol Med (maywood), Oct 2015
UNASSIGNED: Opioid growth factor receptor (OGFr) facilitates growth inhibition in the presence of its specific ligand opioid growth factor (OGF), chemically termed [Met(5)]-enkephalin.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
New
McLaughlin et al., United States. In Exp Biol Med (maywood), Aug 2015
The OGF-OGFr axis can be activated through exogenous administration of OGF or a low dosage of naltrexone (LDN), an opioid antagonist.
Mutations in the opioid growth factor receptor in human cancers alter receptor function.
New
McLaughlin et al., United States. In Int J Mol Med, Jul 2015
The opioid growth factor (OGF)-OGF receptor (OGFr) axis is present and tonically active in animal and human cancer cell lines and tumors.
Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.
Zagon et al., United States. In Bmc Immunol, 2014
The opioid growth factor-opioid growth factor receptor (OGF-OGFr) axis has been shown to effectively limit progression of chronic EAE when mice are treated at the time of induction or at time of established disease.
Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
McLaughlin et al., United States. In Exp Biol Med (maywood), 2014
Naltrexone (NTX) is an opioid receptor antagonist that acts at classical and non-classical opioid receptors including the opioid growth factor receptor (OGFr).
Topical Naltrexone as Treatment for Type 2 Diabetic Cutaneous Wounds.
McLaughlin et al., United States. In Adv Wound Care (new Rochelle), 2014
NTX blocks the opioid growth factor (OGF)-OGF receptor (OGFr) axis and upregulates DNA synthesis and cell proliferation.
Opioid growth factor and the treatment of human pancreatic cancer: a review.
Review
McLaughlin et al., United States. In World J Gastroenterol, 2014
Opioid growth factor (OGF), chemically termed [Met⁵]-enkephalin, and its receptor, OGF receptor (OGFr), form a biological axis that tonically regulates cell proliferation by delaying the G₁/S interface of the cell cycle under homeostatic conditions or in neoplasia.
Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.
McLaughlin et al., United States. In Exp Biol Med (maywood), 2013
These data reveal that complications in wound healing associated with T1D involve the novel OGF-OGFr pathway, and that topical NTX is an effective treatment to enhance wound healing.
Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor.
McLaughlin et al., United States. In Brain Res Bull, 2013
The purpose of this study was to examine the therapeutic efficacy of a novel biological pathway, the opioid growth factor (OGF)-OGF receptor (OGFr) axis.
Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
McLaughlin et al., Penn Hills, United States. In Exp Biol Med (maywood), 2013
The opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis is a determinant of cell proliferation in neoplasia, and OGF is an endogenously produced pentapeptide that inhibits cell replication by interacting with OGFr and upregulating cyclin-dependent inhibitory kinase pathways thus reducing DNA synthesis.
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
McLaughlin et al., United States. In Exp Biol Med (maywood), 2013
The opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis is a biological pathway that is present in human ovarian cancer cells and tissues.
Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure.
GeneRIF
Zagon et al., United States. In Am J Physiol Regul Integr Comp Physiol, 2012
These data demonstrate for the first time that stable genetic amplification of OGFr downregulates homeostatic cell proliferation, as well as pathophysiological processes with respect to wound repair.
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
GeneRIF
Zagon et al., United States. In Exp Biol Med (maywood), 2012
OGF-OGFr axis is a determinant of the progression of human ovarian cancer
Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
Review
Zagon et al., United States. In Brain Res Bull, 2010
The opioid growth factor (OGF)-OGF receptors (OGFr) axis plays an important role in the homeostasis and re-epithelialization of the mammalian cornea.
The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.
GeneRIF
Staveley-O'Carroll et al., United States. In Am J Physiol Regul Integr Comp Physiol, 2010
These data are the first to report that theOGFr system is a native biological regulator of cell proliferation in Hepatocellular carcinoma
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
GeneRIF
McLaughlin et al., United States. In Am J Physiol Regul Integr Comp Physiol, 2009
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
GeneRIF
Goldenberg et al., United States. In Bmc Cancer, 2008
OGF and OGFR are present in follicular-derived thyroid cancers, and that OGF serves in a inhibitory manner to maintain homeostasis of cell proliferation.
The biology of the opioid growth factor receptor (OGFr).
Review
McLaughlin et al., United States. In Brain Res Brain Res Rev, 2002
Subcellular fractionation studies show that the receptor for OGF (OGFr) is an integral membrane protein associated with the nucleus.
share on facebooktweetadd +1mail to friends